A phase II trial of oral gimatecan for recurrent glioblastoma
- 292 Downloads
Gimatecan is a lipophilic oral camptothecin analogue with preclinical activity in glioma models. We conducted a multicenter phase II trial to evaluate the efficacy of gimatecan in adults with recurrent glioblastoma. Eligibility criteria included ≤1 prior treatment for recurrent disease, age ≥18, Eastern Cooperative Oncology Group performance status 0–1, and normal organ function. Patients taking enzyme-inducing anti-seizure medications were excluded. Gimatecan 1.22 mg/m2 was given orally once daily for 5 consecutive days during each 28-day cycle. The primary endpoint was progression-free survival at 6 months. A Simon 2-stage optimal design was used in which 19 patients were evaluated in the 1st stage, with an additional 36 patients accrued if >4 patients in stage 1 achieved PFS at 6 months. 29 patients were enrolled in the study, with median age of 58 years (range, 25–77 years); 58.6 % female. All patients received prior surgery, radiation therapy, and at least one chemotherapy regimen. The daily dose was reduced to 1.0 mg/m2 after four of the first 10 patients experienced grade 4 hematologic toxicity. Treatment-related grade 3/4 toxicities included thrombocytopenia (17.2 %), leukopenia (17.2 %) and neutropenia (10.3 %). None of the 19 patients treated at 1.0 mg/m2/day experienced grade 4 hematologic toxicity. One patient had a partial radiographic response by modified Macdonald criteria. Only 3 patients (12 %) were progression-free at 6 months. Median time to progression was 12.0 weeks (7.0, 17.0).Treatment with gimatecan 1.0 mg/m2/day for 5 days, repeated every 28-days showed minimal efficacy.
KeywordsGimatecan Glioblastoma Clinical trial Camptothecin Brain tumor Glioma
Grant support from Sigma-Tau Research.
Conflict of interest
N. Salem is employed by Sigma-Tau.
This study complies with the current laws of the United States of America.
- 1.Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Groups EOfRaToCBTaR, Group NCIoCCT. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
- 2.Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28:1168–1174PubMedCrossRefGoogle Scholar
- 5.Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17:1516–1525PubMedGoogle Scholar
- 6.Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J, Consortium NABT (2006) A phase II trial of irinotecan (cpt-11) in patients with recurrent malignant glioma: a north american brain tumor consortium study. Neuro–Oncol 8:189–193PubMedGoogle Scholar
- 8.Lopez KA, Tannenbaum AM, Assanah MC, Linskey K, Yun J, Kangarlu A, Gil OD, Canoll P, Bruce JN (2011) Convection-enhanced delivery of topotecan into a pdgf-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors. Cancer Res 71:3963–3971PubMedCrossRefGoogle Scholar
- 9.De Cesare M, Pratesi G, Perego P, Carenini N, Tinelli S, Merlini L, Penco S, Pisano C, Bucci F, Vesci L, Pace S, Capocasa F, Carminati P, Zunino F (2001) Potent antitumor activity and improved pharmacological profile of st1481, a novel 7-substituted camptothecin. Cancer Res 61:7189–7195PubMedGoogle Scholar
- 13.Sessa C, Cresta S, Cerny T, Baselga J, Rota Caremoli E, Malossi A, Hess D, Trigo J, Zucchetti M, D’Incalci M, Zaniboni A, Capri G, Gatti B, Carminati P, Zanna C, Marsoni S, Gianni L (2007) Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (st1481) in patients with advanced solid tumors. Ann Oncol 18:561–568PubMedCrossRefGoogle Scholar
- 14.Boni C, Gamucci T, Bonetti A, Bisagni G, Dall’o’ E, Zanna C, Marsoni S, Sessa C, Azienda Ospedaliera S, Nuova M, Emilia R (2004) A phase II study of the novel oral camptothecin st1481 in pretreated metastatic colorectal cancer (crc). J Clin Onco 3684Google Scholar
- 15.Mariani P, Moliterni A, Da Prada G, Hess D, Gamucci T, Zaniboni A, Malossi A, Barbieri P, Marsoni S, Gianni L (2006) A phase II trial of the novel oral camptothecin gimatecan (g) in women with anthracycline (a) and taxane (t) pre-treated advanced breast cancer. J Clin Oncol 662Google Scholar
- 16.Pecorelli S, Ray-Coquard I, Tredan O, Colombo N, Parma G, Tisi G, Katsaròs D, Lhommé C, Lissoni AA, Vermorken JB, du Bois A, Poveda A, Frigerio L, Barbieri P, Carminati P, Brienza S, Guastalla JP (2010) Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Ann Oncol 21:759–765PubMedCrossRefGoogle Scholar
- 23.Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD, Consortium NABT (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro–Oncol 10:162–170PubMedGoogle Scholar
- 28.Vassal G, Hamelin N, Opolon P, Versace R, Geoerger B (2008) The topoisomerase I inhibitor gimatecan exhibits synergistic antitumor activity in combination with imatinib mesylate and everolimus against malignant glioma xenografts. 2073Google Scholar
- 31.Furuta T, Takemura H, Liao ZY, Aune GJ, Redon C, Sedelnikova OA, Pilch DR, Rogakou EP, Celeste A, Chen HT, Nussenzweig A, Aladjem MI, Bonner WM, Pommier Y (2003) Phosphorylation of histone h2ax and activation of mre11, rad50, and nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA-topoisomerase I cleavage complexes. J Biol Chem 278:20303–20312PubMedCrossRefGoogle Scholar